McGuire Institute
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, McGuire Institute sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
McGuire Institute: 7 sponsored US clinical trials, 1 recruiting.
McGuire Institute sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma In Situ, with 1 trials.
Upper-quartile sponsor footprint
McGuire Institute sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Clinical Trial Comparing Overnight and 2x/Day for 30-minutes Use of the Emanate Perio PODS Post-SRP
NCT06914596
OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier
NCT06447844
Non-Guided vs. Guided Surgery to Immediately Loaded PrimeTaper Implants in Partially Edentulous Patients
NCT05264545
Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery
NCT06919809
Pilot Study for Healing and Safety Outcomes in Gingival Recession
NCT04614350
Controlled Study Comparing REPaiR® and MIST Therapies for Treatment of Periodontitis
NCT04169139
An RCT Comparing Xenograft and Allograft for Ridge Preservation
NCT02330523
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Where McGuire Institute enrollment is open (later-stage tilt)
1 recruiting of 7 indexed (14% open); 4 completed (57%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Melanoma In Situ (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
McGuire Institute: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
McGuire Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this McGuire Institute page
7 registered trials is a research-attention snapshot, not an endorsement of McGuire Institute or any single study.
- 1 of McGuire Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Melanoma In Situ is the condition McGuire Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma In Situ trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. McGuire Institute pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.